OBD vs. ONC, FAB, BVX, CIZ, GENF, APTA, IXI, ROQ, SNG, and EVG
Should you be buying Oxford BioDynamics stock or one of its competitors? The main competitors of Oxford BioDynamics include Oncimmune (ONC), Fusion Antibodies (FAB), BiVictriX Therapeutics (BVX), Cizzle Biotechnology (CIZ), Genflow Biosciences (GENF), Aptamer Group (APTA), IXICO (IXI), Roquefort Therapeutics (ROQ), Synairgen (SNG), and Evgen Pharma (EVG). These companies are all part of the "biotechnology" industry.
Oxford BioDynamics vs.
Oxford BioDynamics (LON:OBD) and Oncimmune (LON:ONC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.
Oxford BioDynamics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Oncimmune has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
Oncimmune has higher revenue and earnings than Oxford BioDynamics. Oncimmune is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.
44.3% of Oxford BioDynamics shares are held by institutional investors. Comparatively, 25.0% of Oncimmune shares are held by institutional investors. 16.8% of Oxford BioDynamics shares are held by company insiders. Comparatively, 31.0% of Oncimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Oxford BioDynamics received 36 more outperform votes than Oncimmune when rated by MarketBeat users. Likewise, 60.82% of users gave Oxford BioDynamics an outperform vote while only 59.13% of users gave Oncimmune an outperform vote.
In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled Oncimmune'saverage media sentiment score.
Oncimmune has a net margin of 586.08% compared to Oxford BioDynamics' net margin of 0.00%. Oxford BioDynamics' return on equity of -266.70% beat Oncimmune's return on equity.
Summary
Oncimmune beats Oxford BioDynamics on 7 of the 13 factors compared between the two stocks.
Get Oxford BioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford BioDynamics Competitors List
Related Companies and Tools
This page (LON:OBD) was last updated on 1/22/2025 by MarketBeat.com Staff
Free OBD Stock Alerts